Laboratorios Farmaceuticos Rovi, S.A. (BME: ROVI)

Market Cap	3.14B
Revenue (ttm)	799.25M
Net Income (ttm)	165.00M
Shares Out	51.15M
EPS (ttm)	3.09
PE Ratio	19.86
Forward PE	18.56
Dividend	1.10 (1.80%)
Ex-Dividend Date	Jul 8, 2024

Volume	99,230
Open	60.65
Previous Close	60.95
Day's Range	59.25 - 61.55
52-Week Range	59.00 - 94.80
Beta	0.51
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 21, 2025

About BME: ROVI

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women’s health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Nepar...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1946
• Employees: 2,111
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: ROVI

Financial Performance

In 2023, ROVI's revenue was 829.51 million, an increase of 1.44% compared to the previous year's 817.70 million. Earnings were 170.34 million, a decrease of -14.69%.